Blog

The nine new countries set to receive the malaria vaccine, developed by British drugmaker GSK (GSK.L), are Benin, Burkina Faso, Burundi, Cameroon, the Democratic Republic of the Congo, Liberia, Niger, Sierra Leone, and Uganda. The first doses of the RTS-S vaccine are expected to reach the 12 African countries during the last quarter of 2023, allowing them to start rolling out by early next year. This significant development marks a major milestone in the fight against malaria, a disease that has plagued these regions for far too long. The inclusion of these nine countries in the vaccination program demonstrates a collective effort to eradicate malaria and improve public health across Africa. GSK’s RTS-S vaccine has shown promising results in clinical trials, offering hope for a brighter future. With the arrival of the first doses anticipated in late 2023, there is an urgent need to ensure efficient distribution and administration to maximize their impact. By early next year, these countries will be equipped to initiate widespread vaccination campaigns, reaching vulnerable populations and safeguarding countless lives from the devastating effects of malaria. This initiative not only showcases the power of collaboration but also highlights the commitment of global health organizations and governments towards achieving a malaria-free world. As we move forward, it is crucial to maintain momentum and expand access to this life-saving vaccine, ultimately paving the way for a healthier and more resilient Africa. The Framework implementation group that applied the framework principles included representatives of the Africa Centers for Disease Control and Prevention (Africa CDC), UNICEF, WHO, and the Gavi Secretariat, as well as representatives of civil society and independent advisors. The group’s recommendations were reviewed and endorsed by the Senior Leadership Endorsement Group of Gavi, WHO, and UNICEF.